394 related articles for article (PubMed ID: 9180298)
1. Autologous bone marrow purging by in situ IL-2 activation of endogenous killer cells.
Margolin KA; Wright C; Forman SJ
Leukemia; 1997 May; 11(5):723-8. PubMed ID: 9180298
[TBL] [Abstract][Full Text] [Related]
2. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG
Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943
[TBL] [Abstract][Full Text] [Related]
3. Lymphokine-activated killer function following autologous bone marrow transplantation for refractory hematological malignancies.
Higuchi CM; Thompson JA; Cox T; Lindgren CG; Buckner CD; Fefer A
Cancer Res; 1989 Oct; 49(20):5509-13. PubMed ID: 2477142
[TBL] [Abstract][Full Text] [Related]
4. Induction by interleukin-7 of lymphokine-activated killer activity in lymphocytes from autologous and syngeneic marrow transplant recipients before and after systemic interleukin-2 therapy.
Pavletic Z; Benyunes MC; Thompson JA; Lindgren CG; Massumoto C; Alderson MR; Buckner CD; Fefer A
Exp Hematol; 1993 Sep; 21(10):1371-8. PubMed ID: 8359237
[TBL] [Abstract][Full Text] [Related]
5. Lymphokine-activated killer cells selectively kill tumor cells in bone marrow without compromising bone marrow stem cell function in vitro.
van den Brink MR; Voogt PJ; Marijt WA; van Luxemburg-Heys SA; van Rood JJ; Brand A
Blood; 1989 Jul; 74(1):354-60. PubMed ID: 2787676
[TBL] [Abstract][Full Text] [Related]
6. Natural killer and lymphokine-activated killer cell activities from human marrow precursors. II. The effects of IL-3 and IL-4.
Keever CA; Pekle K; Gazzola MV; Collins NH; Bourhis JH; Gillio A
J Immunol; 1989 Nov; 143(10):3241-9. PubMed ID: 2809200
[TBL] [Abstract][Full Text] [Related]
7. Design and validation of a clinically applicable culture procedure for the generation of interleukin-2 activated natural killer cells in human bone marrow autografts.
Klingemann HG; Deal H; Reid D; Eaves CJ
Exp Hematol; 1993 Aug; 21(9):1263-70. PubMed ID: 8330650
[TBL] [Abstract][Full Text] [Related]
8. Susceptibility of human leukemia to allogeneic and autologous lymphokine-activated killer cell activity: analysis of 252 samples.
Teichmann JV; Ludwig WD; Thiel E
Nat Immun; 1992; 11(3):117-32. PubMed ID: 1392400
[TBL] [Abstract][Full Text] [Related]
9. Generation of lymphokine-activated killer (LAK) cells and possible implications in autologous bone marrow transplantation--a preliminary report.
Tzeng CH; Chuang MW; Wang SY; Hsieh RK; Liu CJ; Fan S; Chen PM
Proc Natl Sci Counc Repub China B; 1990 Jan; 14(1):47-53. PubMed ID: 2381997
[TBL] [Abstract][Full Text] [Related]
10. Culture of normal and leukemic bone marrow in interleukin-2: analysis of cell activation, cell proliferation, and cytokine production.
Klingemann HG; Neerunjun J; Schwulera U; Ziltener HJ
Leukemia; 1993 Sep; 7(9):1389-93. PubMed ID: 8371589
[TBL] [Abstract][Full Text] [Related]
11. Generation of LAK cells in vitro in patients with acute leukemia.
Parrado A; Rodriguez-Fernandez JM; Casares S; Noguerol P; Plaza E; Parody R; Espigado I; de Blas JM; Garcia-Solis D
Leukemia; 1993 Sep; 7(9):1344-8. PubMed ID: 8371585
[TBL] [Abstract][Full Text] [Related]
12. Lymphokine-activated killer cell purging of leukemia cells from bone marrow prior to syngeneic transplantation.
Long GS; Hiserodt JC; Harnaha JB; Cramer DV
Transplantation; 1988 Sep; 46(3):433-8. PubMed ID: 2901797
[TBL] [Abstract][Full Text] [Related]
13. Anti-CD3 + interleukin-2 stimulation of marrow and blood: comparison of proliferation and cytotoxicity.
Anderson PM; Ochoa AC; Ramsay NK; Hasz D; Weisdorf D
Blood; 1992 Oct; 80(7):1846-53. PubMed ID: 1391948
[TBL] [Abstract][Full Text] [Related]
14. Lymphokine-activated killer (LAK) cell purging of leukemic bone marrow: range of activity against different hematopoietic neoplasms.
Long GS; Cramer DV; Harnaha JB; Hiserodt JC
Bone Marrow Transplant; 1990 Sep; 6(3):169-77. PubMed ID: 2252956
[TBL] [Abstract][Full Text] [Related]
15. Interleukin 2 induction of lymphokine-activated killer (LAK) activity in the peripheral blood and bone marrow of acute leukemia patients. I. Feasibility of LAK generation in adult patients with active disease and in remission.
Adler A; Chervenick PA; Whiteside TL; Lotzová E; Herberman RB
Blood; 1988 Mar; 71(3):709-16. PubMed ID: 3257887
[TBL] [Abstract][Full Text] [Related]
16. Cytotoxicity of interleukin 2-induced lymphokine-activated killer (LAK) cells against human leukemia and augmentation of killing by interferons and tumor necrosis factor.
Teichmann JV; Ludwig WD; Thiel E
Leuk Res; 1992; 16(3):287-98. PubMed ID: 1560676
[TBL] [Abstract][Full Text] [Related]
17. Cytotoxicity of interleukin 2-activated lymphocytes for leukemia and lymphoma cells.
Oshimi K; Oshimi Y; Akutsu M; Takei Y; Saito H; Okada M; Mizoguchi H
Blood; 1986 Oct; 68(4):938-48. PubMed ID: 3489494
[TBL] [Abstract][Full Text] [Related]
18. Lymphokine-activated killer (LAK) cell generation from peripheral blood stem cells by in vitro incubation with low-dose interleukin-2 plus granulocyte-macrophage colony-stimulating factor.
Herrera C; García-Pérez MJ; Ramirez R; Martín C; Alvarez MA; Martinez F; Gómez P; García-Castellano JM; Torres A
Bone Marrow Transplant; 1997 Mar; 19(6):545-51. PubMed ID: 9085733
[TBL] [Abstract][Full Text] [Related]
19. Autologous activated natural killer cells suppress primitive chronic myelogenous leukemia progenitors in long-term culture.
Cervantes F; Pierson BA; McGlave PB; Verfaillie CM; Miller JS
Blood; 1996 Mar; 87(6):2476-85. PubMed ID: 8630414
[TBL] [Abstract][Full Text] [Related]
20. Adherent lymphokine-activated killer cells suppress autologous human normal bone marrow progenitors.
Miller JS; Verfaillie C; McGlave P
Blood; 1991 Jun; 77(11):2389-95. PubMed ID: 1903991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
